Enrolling by invitationNo phase
CHU Dual-Energy Ablation in Ventricular Arrhythmia
Key facts
- Who runs it
- Shanghai MicroPort EP MedTech Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Enrolling by invitation
- People taking part
- 10 people, planned
- Started
- 3 Feb 2026
- Planned end
- 31 Oct 2026
- Type of study
- Interventional
- Treatments tested
- ablation
- Record updated
- 31 March 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Patient age ≥ 18 years and ≤ 75 years；
- Clinically diagnosed with tachyarrhythmia, specifically idiopathic ventricular arrhythmia；
- Recurrent disease with obvious symptoms prior to enrollment
- Failure to respond to or intolerance of at least one antiarrhythmic drug
- Fully understand the treatment plan, voluntarily sign the informed consent form, and agree to undergo the examinations, procedures and follow-up as required by the protocol
Who cannot take part
- Previous atrial septal repair or atrial myxoma
- Patients who have participated in or are currently participating in other clinical trials within 3 months prior to enrollment
- History of ventricular flutter or ventricular fibrillation
- Presence of structural heart disease or organic heart disease, including hypertrophic cardiomyopathy, dilated cardiomyopathy, ischemic cardiomyopathy, rheumatic heart disease, and congenital heart disease
- Carrying an active implantable device in the body (e.g., cardiac pacemaker, ICD, etc.)
- Patients with documented cerebrovascular disease within the past 6 months (including cerebral hemorrhage, stroke, transient ischemic attack)
- Patients with cardiovascular events within the past 3 months (including acute myocardial infarction, percutaneous coronary intervention or coronary artery bypass grafting, prosthetic valve replacement or repair, atrial or ventricular incision)
- Patients with acute or severe systemic infection
- Patients with severe hepatic or renal disease, malignant tumor, or end-stage disease, who, in the investigator's judgment, may interfere with the treatment, evaluation, or compliance of this trial
- Patients with significant bleeding tendency, hypercoagulable state, or severe hematological disorders
- Patients with other conditions deemed inappropriate for participation in this trial by the investigator
- Left ventricular ejection fraction (LVEF) ≤ 40%
- Diagnosis of long QT syndrome or arrhythmogenic cardiomyopathy
- NYHA functional class Ⅲ-Ⅳ
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objective of this study is to evaluate the safety of the dual-energy ablation catheter manufactured by Shanghai MicroPort EP Medical Technology Co., Ltd. in the treatment of tachyarrhythmias.
The group in the trial
- Catheter ablationTreatment being tested
All enrolled subjects will undergo radiofrequency or pulsed ablation for idiopathic ventricular arrhythmias using the investigational catheter.
Treatment: ablation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Contact-Force Guided Hybrid-Dual-Energy Ultra-Saline-Irrigated Ablation First-in-Man for Ventricular Arrhythmia: CHU VA
- Fit questions
- Built from NCT07503769, who can take part
- Record updated
- 31 March 2026